Who are enGene Therapeutics Inc.'s main suppliers?

enGene Therapeutics Inc. (ENGNW) key suppliers include: Aura Biosciences, Inc., Aura Biosciences, Inc., Johnson & Johnson, Johnson & Johnson, Protara Therapeutics, Inc. and 1 more. View the full supplier network at chainsifter.com/chain/ENGNW.

Who are enGene Therapeutics Inc.'s major customers?

enGene Therapeutics Inc. (ENGNW) key customers include: Aura Biosciences, Inc., Aura Biosciences, Inc., Johnson & Johnson, Johnson & Johnson, Protara Therapeutics, Inc. and 1 more. View the full customer network at chainsifter.com/chain/ENGNW.

What sector is enGene Therapeutics Inc. in?

enGene Therapeutics Inc. (ENGNW) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

enGene Therapeutics Inc. Suppliers, Customers & Supply Chain (ENGNW)

6Suppliers

6Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

enGene Therapeutics Inc. (ENGNW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

14Total relationships

2Distinct source URLs

2High confidence

0.746Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

enGene Therapeutics Inc. Suppliers

Ticker	Name	Confidence	Evidence
AURA	Aura Biosciences, Inc.	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
AURA	Aura Biosciences, Inc.	72%	Reciprocal relationship from AURA graph: Reciprocal relationship from ENGNW graph: nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe ca…
JNJ	Johnson & Johnson	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from ENGNW graph: nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can…
TARA	Protara Therapeutics, Inc.	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
TARA	Protara Therapeutics, Inc.	72%	Reciprocal relationship from TARA graph: Reciprocal relationship from ENGNW graph: nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe ca…

enGene Therapeutics Inc. Customers

Ticker	Name	Confidence	Evidence
AURA	Aura Biosciences, Inc.	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
AURA	Aura Biosciences, Inc.	72%	Reciprocal relationship from AURA graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from AURA graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from AURA…
JNJ	Johnson & Johnson	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from JNJ gr…
TARA	Protara Therapeutics, Inc.	72%	nts, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive N…
TARA	Protara Therapeutics, Inc.	72%	Reciprocal relationship from TARA graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from TARA graph: Reciprocal relationship from ENGNW graph: Reciprocal relationship from TARA…

enGene Therapeutics Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ENGNW-DEBT-9304	Warrants outstanding: 11.5	90%	xbrl warrant detail from xbrl 2024-10-31.
ENGNW-DEBT-9305	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-10-31.

enGene Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for enGene Therapeutics Inc..

enGene Therapeutics Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for enGene Therapeutics Inc..

enGene Therapeutics Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
TARA	Protara Therapeutics, Inc.	100.00	1	['customer', 'supplier']
AURA	Aura Biosciences, Inc.	100.00	1	['customer', 'supplier']
BLLN	BillionToOne, Inc.	50.00	2
AORT	Artivion, Inc.	50.00	2
AVBP	ArriVent BioPharma, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
FCX	Freeport-McMoRan Inc.	50.00	2
CBIH	Cannabis Bioscience International Holdings, Inc.	50.00	2
BNR	Burning Rock Biotech Limited	50.00	2
BNRG	Brenmiller Energy Ltd	50.00	2
AVTX	Avalo Therapeutics, Inc.	50.00	2
CSTE	Caesarstone Ltd.	50.00	2
CVRX	CVRx, Inc.	50.00	2
DYAI	Dyadic International, Inc.	50.00	2
SNNUF	Smith & Nephew plc	50.00	2
ALC	Alcon Inc.	50.00	2
ATNM	Actinium Pharmaceuticals, Inc.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2

enGene Therapeutics Inc. Supply Chain